USFDA classifies Aurobindo Pharma Inc's warehouse as OAI

The United States Food and Drug Administration (US FDA) had conducted an inspection at one of the warehouses of Aurobindo Pharma USA Inc., (a 100% subsidiary of the Company), situated at East Windsor, New Jersey, from May 13, 2024 to May 15, 2024, with regards to compliance of the Drug Supply Chain Security Act (DSCSA). The inspection had concluded with 5 observations.

Subsequently, the US FDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated (OAI)'.

At this point in time, the Company doesn't foresee any impact on the business.

The Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1136.30 as compared to the previous close of Rs. 1164.05. The total number of shares traded during the day was 108206 in over 6728 trades.

The stock hit an intraday high of Rs. 1138.75 and intraday low of 1053.45. The net turnover during the day was Rs. 120562736.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 USASubsidiary USFDA Inspection